A practical reference on systematic review: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Hygroscopic; let the vial equilibrate before opening |
| Solubility | Freely soluble in water and aqueous buffers | Working solutions are often prepared between 0.1 and 1 mg per mL |
| Typical storage temperature | At or below 20 degrees below zero Celsius | Desiccant and sealed vials reduce moisture uptake |
| Routine purity assay | Reversed-phase HPLC with ultraviolet detection | Result reported as percentage of total peak area |
| Identity check | Mass spectrometry with amino acid analysis | Observed mass is compared with the calculated value |
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
== See also == Breaking Bad – TV drama series centered on illicit methamphetamine synthesis Drug checking – Harm reduction technique Faces of Meth – Drug prevention project Famprofazone – Non-steroidal anti-inflammatory drug yielding methamphetamine as a major metabolite Harm reduction – Public health policies which lessen negative aspects of problematic activities Methamphetamine and Native Americans Methamphetamine in Australia Methamphetamine in Bangladesh – Illegal mix of methamphetamine and caffeine Methamphetamine in the Philippines Methamphetamine in the United States Montana Meth Project – Montana-based organization aiming to reduce meth use among teenagers Recreational drug use – Use of drugs with the primary intention to alter the state of consciousness Rolling meth lab – A transportable laboratory that is used to illegally produce methamphetamine Ya ba – Southeast Asian tablets containing a mixture of methamphetamine and caffeine
10 June The VC announced that it had selected leaders for its "Provisional Revolutionary Government of the Republic of South Vietnam" (PRG), a "government in exile" to assume leadership if the VC and North Vietnam were successful in conquering South Vietnam. Former South Vietnamese lawyer and VC president Nguyễn Hữu Thọ was named as chairman of the advisory council to the PRG, and Huỳnh Tấn Phát was named the PRG Council President.
The number of diseases screened for is set by each jurisdiction, and can vary greatly. Most NBS tests are done by measuring metabolites or enzyme activity in whole blood samples collected on filter paper. Bedside tests for hearing loss using automated auditory brainstem response or otoacoustic emissions and congenital heart defects using pulse oximetry are included in some NBS programs. Infants who screen positive undergo further testing to determine if they are truly affected with a disease or if the test result was a false positive. Follow-up testing is typically coordinated between geneticists and the infant's pediatrician or primary care physician.
Sources: en.wikipedia.org
== W == Wada test A procedure used to determine language and memory functions in each hemisphere of the brain. It involves anesthetizing one hemisphere at a time, usually with sodium amobarbital, and is commonly performed prior to epilepsy surgery. Wallerian degeneration A process of degeneration that occurs in an axon distal to the site of injury. It is a key feature of nerve damage in both the central and peripheral nervous systems. Waxy flexibility A psychomotor symptom often associated with catatonia and schizophrenia in which a patient’s limbs remain in a fixed position after being moved by someone else. Weber–Fechner law A principle in sensory neuroscience that describes the relationship between the magnitude of a physical stimulus and the perceived intensity. Suggests logarithmic scaling of sensation. Wernicke's area A region of the posterior superior temporal gyrus in the dominant hemisphere, involved in language comprehension. Damage here causes Wernicke’s aphasia, which impairs understanding of spoken and written language. Wernicke's encephalopathy A neurological condition caused by thiamine deficiency, typically seen in chronic alcoholics. It manifests with a triad of symptoms: confusion, ataxia, and ophthalmoplegia. West syndrome A severe form of epilepsy in infancy characterized by infantile spasms, developmental regression, and a distinctive EEG pattern called hypsarrhythmia. White matter Tissue in the brain and spinal cord composed primarily of myelinated axons, facilitating communication between gray matter regions.
=== Offices (Ämter) === Ämter ("offices" or "bureaus"): in some states, there is an administrative unit between the districts and the municipalities, called Ämter (singular Amt), Amtsgemeinden, Gemeindeverwaltungsverbände, Landgemeinden, Verbandsgemeinden, Verwaltungsgemeinschaften, or Kirchspiellandgemeinden.
== Classification == Kwashiorkor is a type of severe acute malnutrition (SAM). SAM is a category, composed of two conditions: marasmus and kwashiorkor. Both kwashiorkor and marasmus fall under the umbrella of protein–energy malnutrition (PEM). These diseases are oftentimes discussed together, but are distinctly separate conditions of malnutrition. Kwashiorkor is marked by an array of metabolic disturbances of uncertain cause. In contrast, marasmus is more clearly an energy deficiency syndrome, marked by weight loss. On physical exam, kwashiorkor is also distinguished from marasmus by the presence of edema. When children present with both kwashiorkor and marasmus, the condition is referred to as "marasmic-kwashiorkor". In general, kwashiorkor is marked by more profound serum depletions of antioxidant molecules and minerals, relative to marasmus.
=== Legal status === In April 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Adtralza, intended for the treatment of moderate‑to‑severe atopic dermatitis. The applicant for this medicinal product is LEO Pharma A/S. Tralokinumab was approved for medical use in the European Union in June 2021.
Sources: en.wikipedia.org
Their mission, in their words "for the purpose of mutual aid in cases of sickness, accident and death of its members or their families". In 1923 it had 8,000 members in 60 subordinate societies; that year it had a capital of over $500,000, with a further $100,000 in sick benefit funds held by local societies. All policy decisions are determined by a "Central Society" made up of the officers, founders, and representatives of the subordinate lodges. A central society meets at stated intervals to elect officers to administer the group and make needed changes. Membership is open to men 18–50, of good moral character who have passed medical exams, regardless of religious or political creeds. Germania stated that it "is not a secret society. No pass-words or grips feature its work. In fact, any man is welcome to join its meetings." German Order of Harugari Greater Beneficial Union of Pittsburgh - Incorporated April 14, 1892 in Allegheny County, Pennsylvania, as the Deutscher Unter-stuetzungs-Bund, within a month had 243 members in 6 districts. Began the periodical, Union Reporter, the next year, now known as GBU Reporter. Rituals include the candidate signing an application and the president of the local lodge giving an address about the privileges of membership and how one should enter the lodge. Union claimed to be non-sectarian and had no secrets; open to all "well-meaning persons"; non-members accompanied by members allowed at meeting.
A nasal skin defect of less than 15 mm in diameter can be managed with a bilobed flap; the surgeon trims the edges of the wound (defect) to match its dimensions (length, width, depth) to the natural curve at the border of the nasal tip. If the wound is eccentric, the skin-flap is positioned so that the lateral base of the graft occupies the largest portion of the wound's surface. If the nasal-tip wound is greater than 15 mm in diameter, the surgeon enlarges it to comprehend the entire aesthetic subunit affected by the defect, and the reconstruction of the nasal subunit done with a forehead flap. If the nasal-tip defect also involves the nasal dorsum, a forehead flap is indicated for reconstructing the entire nasal-tip and dorsum. If an alar cartilage is missing, either partially or entirely, it is reconstructed with cartilage grafts. The defect of an alar dome, which retains adequate anatomic support-tripod configuration, can be corrected with an onlay graft harvested either from the nasal septum or from the conchal cartilage of an ear. The surgeon forms the cartilage graft into the shape of a shield—its widest margins become the replacement alar domes. Typically, the shield cartilage graft is stacked in two layers, in order to transmit the desired light reflex characteristic of the nasal tip. Defects of the lateral crura can be corrected with a flat strut of formed cartilage, but, if the support of the medial crura is absent, then a columella strut must be inserted, and attached at the level of the anterior nasal spine.
== Illegal importation of ineffective version into the UK == Monovalent mumps vaccine (Mumpsvax) remained available in the US when MMR was introduced in the UK, replacing the MR (measles and rubella) mixed vaccine. No UK-licensed monovalent preparation was ever available. Monovalent mumps vaccines were available before MMR, but only used on a limited scale. This became the subject of considerable argument at the end of the 20th century, since some parents preferred to obtain individually the components of the MMR mixture. One unlicensed mumps vaccine preparation imported into the United Kingdom proved to be essentially ineffective. Immunisation against mumps in the UK became routine in 1988, commencing with MMR. The Aventis-Pasteur "MMR-2" brand is usual in the UK in 2006.
Sources: en.wikipedia.org
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.
Research material is commonly offered at 95 percent purity or above by chromatographic area, with some suppliers listing 98 percent. Higher grades usually carry a higher price and are chosen when the assay is sensitive to trace impurities.
Mass spectrometry is the standard check, often paired with amino acid analysis or peptide mapping. A chromatographic retention time alone is generally considered insufficient for structural confirmation.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.